← Back to Clinical Trials
Recruiting NCT07354568

NCT07354568 Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07354568
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Cardiogenic Shock Acute
Study Type OBSERVATIONAL
Enrollment 2,500 participants
Start Date 2025-10-20
Primary Completion 2027-01-01

Trial Parameters

Condition Cardiogenic Shock Acute
Sponsor Centre Hospitalier Universitaire, Amiens
Study Type OBSERVATIONAL
Phase N/A
Enrollment 2,500
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-10-20
Completion 2027-01-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Mixed cardiogenic-vasoplegic shock (M-CS) represents a distinct and severe phenotype of cardiogenic shock characterized by concomitant myocardial dysfunction and inappropriate systemic vasodilation. Despite its clinical relevance, the epidemiology, management, and outcomes of M-CS remain poorly defined. This retrospective, multicenter, observational registry aims to evaluate the clinical outcomes and prognostic factors associated with mixed cardiogenic-vasoplegic shock. The study will analyze clinical, biological, and invasive hemodynamic data routinely collected during patient management for M-CS. All included patients will have been admitted for cardiogenic shock, with or without vasoplegia, defined by low cardiac output and, when present, decreased systemic vascular resistance despite adequate filling pressures requiring vasopressor support. The primary objective is to describe mortality and organ failure rates, while secondary analyses will identify determinants of adverse outcomes and potential phenotypic subgroups. The PROMIX registry will be conducted across three French university hospitals (CHU Amiens-Picardie, CHU Dijon-Bourgogne, and CHU Rouen-Normandie). This study is non-interventional, involving only data obtained as part of routine critical care, and will provide the first multicenter overview of this complex and underrecognized form of cardiogenic shock.

Eligibility Criteria

Inclusion Criteria: * Adult patient (\>18 years old) * Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C * No opposition to data use Exclusion Criteria: * Missing key data, particularly regarding vasopressor doses and outcomes. * Pregnant women * Non-eligible shock etiologies, including but not limited to: * Anaphylactic shock, * Isolated hemorrhagic shock, * Severe burns or major trauma, * Severe acute pancreatitis, * Fulminant hepatic failure, * Neurogenic shock. * Adult under legal protection (guardianship, curatorship, or judicial protection).

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology